Young Woo Eom

Prof. Young Woo Eom

Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju, Gangwon-do, 26426 Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2005 in Oncogene
Verified
Journal Article
Closed access
YEYoung Woo Eom
Young Woo Eom
MKMi Ae Kim
Mi Ae Kim
SPSeok Soon Park
Seok Soon Park
MGMi Jin Goo
Mi Jin Goo
HKHyuk Jae Kwon
Hyuk Jae Kwon
KCKyeong Sook Choi
Kyeong Sook Choi

27 August 2015 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
YEYoung Woo Eom
Young Woo Eom
KSKwang Yong Shim
Kwang Yong Shim
SBSoon Koo Baik
Soon Koo Baik
Currently, the most effective treatment for end-stage liver fibrosis is liver transplantation; however, transplantation is limited by a shortage of donor organs, surgical complications, immunological rejection, and high medical costs. Recently, mesenchymal stem cell (MSC) therapy has been suggested as an effective alternate approach for the treatment of hepatic diseases. MSCs have the potential to differentiate into hepatocytes, and therapeutic value exists in their immune-modulatory properties and secretion of trophic factors, such as growth factors and cytokines. In addition, MSCs can suppress inflammatory responses, reduce hepatocyte apoptosis, increase hepatocyte regeneration, regress liver fibrosis and enhance liver functionality. Despite these advantages, issues remain; MSCs also have fibrogenic potential and the capacity to promote tumor cell growth and oncogenicity. This paper summarizes the properties of MSCs for regenerative medicine and their therapeutic mechanisms and clinical application in the treatment of liver fibrosis. We also present several outstanding risks, including their fibrogenic potential and their capacity to promote pre-existing tumor cell growth and oncogenicity.

1 June 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
MAMohammed Alfaifi
Mohammed Alfaifi
YEYoung Woo Eom
Young Woo Eom
PNPhilip Noel Newsome
Philip Noel Newsome
SBSoon Koo Baik
Soon Koo Baik

1 October 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CWChang-Hoon Woo
Chang-Hoon Woo
YEYoung Woo Eom
Young Woo Eom
MYMin-Hyuk Yoo
Min-Hyuk Yoo
HYHae-Jin You
Hae-Jin You
Ho Jae HanHo Jae Han
Ho Jae Han
Jae-hong KimJae-hong Kim
Jae-hong Kim
Reactive oxygen species (ROS) are important regulatory molecules implicated in the signaling cascade triggered by tumor necrosis factor (TNF)-alpha, although the events through which TNF-alpha induces ROS generation are not yet well characterized. We therefore investigated selected candidates likely to mediate TNF-alpha-induced ROS generation. Consistent with the role of Rac in that process, stable expression of Rac(Asn-17), a dominant negative Rac1 mutant, completely blocked TNF-alpha-induced ROS generation. To understand better the mediators downstream of Rac, we investigated the involvement of cytosolic phospholipase A(2) (cPLA(2)) activation and metabolism of the resultant arachidonic acid (AA) by 5-lipoxygenase (5-LO). TNF-alpha-induced ROS generation was blocked by inhibition of cPLA(2) or 5-LO, but not cyclooxygenase, suggesting that TNF-alpha-induced ROS generation is dependent on synthesis of AA and its subsequent metabolism to leukotrienes. Consistent with that hypothesis, TNF-alpha Rac-dependently stimulated endogenous production of leukotriene B(4) (LTB(4)), while exogenous application of LTB(4) increased levels of ROS. In contrast, application of leukotrienes C(4), D(4), and E(4) or prostaglandin E(2) had little effect. Our findings suggest that LTB(4) production by 5-LO is situated downstream of the Rac-cPLA(2) cascade, and we conclude that Rac, cPLA(2), and LTB(4) play pivotal roles in the ROS-generating cascade triggered by TNF-alpha.

Verified
Journal Article
Open access
PDF file
KRKi-Jong Rhee
Ki-Jong Rhee
JLJONG IN LEE
JONG IN LEE
YEYoung Woo Eom
Young Woo Eom
Mesenchymal stem cells (MSCs) can exhibit a marked tropism towards site of tumors. Many studies have reported that tumor progression and metastasis increase by MSCs. In contrast, other studies have shown that MSCs suppress growth of tumors. MSCs contribute to tumor growth promotion by several mechanisms: (1) transition to tumor-associated fibroblasts; (2) suppression of immune response; (3) promotion of angiogenesis; (4) stimulation of epithelial-mesenchymal transition (EMT); (5) contribution to the tumor microenvironment; (6) inhibition of tumor cell apoptosis; and (7) promotion of tumor metastasis. In contrast to the tumor-promoting properties, MSCs inhibit tumor growth by increasing inflammatory infiltration, inhibiting angiogenesis, suppressing Wnt signaling and AKT signaling, and inducing cell cycle arrest and apoptosis. In this review, we will discuss potential mechanisms by which MSC mediates tumor support or suppression and then the possible tumor-specific therapeutic strategies using MSCs as delivery vehicles, based on their homing potential to tumors.

19 June 2013 in Liver International
Verified
Journal Article
Closed access
PDF file
YJYoon Ok Jang
Yoon Ok Jang
YKYoung Ju Kim
Young Ju Kim
SBSoon Koo Baik
Soon Koo Baik
MKMoon Young Kim
Moon Young Kim
YEYoung Woo Eom
Young Woo Eom
YKYong Man Kim
Yong Man Kim